Alagebrium: Phase IIb data

In the double-blind, placebo-controlled, U.S. Phase IIb SAPPHIRE/SILVER trial, alagebrium reduced SBP in patients with a baseline 24-hour ambulatory SBP >=140 mmHg. In a difficult-to-treat population ...